Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$13.47 USD
-1.37 (-9.23%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $13.48 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Earnings News For VRDN
-
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates
-
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
-
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
-
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
-
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates
-
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for
-
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
-
Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
-
Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
-
Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
-
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
-
Viridian Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
-
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
-
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
-
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Misses Revenue Estimates
-
Will Viridian Therapeutics, Inc. (VRDN) Report Negative Earnings Next Week? What You Should Know
-
Will Viridian Therapeutics, Inc. (VRDN) Report Negative Q4 Earnings? What You Should Know